Feature | March 17, 2015

Five-Year Outcomes for High-Risk Sapien Patients Demonstrate Equivalence To Surgery

PARTNER trial results indicate use for transcatheter aortic valve beyond inoperable patients

Edwards, Sapien, PARTNER trial, five-year outcomes, ACC

March 17, 2015 — Five-year data suggest that the Sapien transcatheter heart valve (Edwards Lifesciences) is a feasible option for patients with severe aortic stenosis deemed to be at high risk for open-heart surgery, though valve leakage was more common with the first-generation valve evaluated in this study than with surgery, according to research from PARTNER I presented at the American College of Cardiology’s (ACC) 2015 Annual Scientific Session. 

The final final five-year clinical data for high-risk patients treated with the first-generation Sapien transcatheter aortic valve in The PARTNER Trial demonstrated equivalent outcomes to traditional open-heart surgery. There was also no structural valve deterioration requiring intervention. Data from the prospective randomized trial for transcatheter aortic valve replacement (TAVR) in patients at high risk for surgery were presented as part of the late-breaking clinical trials at ACC and simultaneously published in The Lancet.

"It's remarkable that this five-year data report continues to show equivalency between what was then a brand new procedure with a first-generation TAVR device and the gold standard of surgery, which has been honed over 50 years of experience," said Michael Mack, M.D., chair, cardiovascular service line, Baylor Scott and White Health.  "Just as we observed in the five-year report from The PARTNER Trial on outcomes in inoperable patients treated with Sapien, the high-risk patients also had durable valve performance. These data show that TAVR is an effective treatment for these patients."  

The authors noted no significant differences in all-cause mortality, cardiovascular mortality, stroke or need for repeat hospitalization. 

“The surprise is that there were no surprises,” Mack said. “The findings at five years confirm the earlier findings that outcomes are equivalent in high-risk surgical patients with surgery and with TAVR.” There were no signs of structural valve deterioration or loss of valve function with TAVR, he said.

The high-risk surgery cohort (Cohort A) of The PARTNER Trial enrolled between May 2007 and September 2009 and studied 699 patients with severe, symptomatic aortic stenosis deemed at high risk for traditional open-heart surgery. Patients were evaluated by a multidisciplinary heart team and randomized to receive either traditional open-heart surgery or the Edwards Sapien valve with transfemoral or transapical delivery. This trial represented the initial TAVR experience for most trial sites in the United States.

At five years, death and stroke rates were statistically the same in both groups: 67.8 percent of TAVR patients and 62.4 percent of surgery patients had died, with median survival of 44.5 months with TAVR and 40.6 months with surgery. Stroke rates were 15.9 percent for TAVR patients and 14.7 percent for surgery patients. Rehospitalization rates and functional outcomes also were the same in both groups.

Transcatheter valves have not approached the low leakage rate around the valve that can be achieved by an open-heart operation. As in previous findings, the rate of moderate or severe leaking around the valve remained significantly higher for the TAVR group — 14 percent with TAVR and 2.1 percent with surgery — and at five years, that higher leakage rate still led to an increase in deaths with the death rate in patients with leakage 9 percent greater than in patients who didn’t have a significant leak. The firstgeneration valve used in this trial has already been replaced by a second-generation device that is approved in the United States, and a third-generation valve has been designed specifically to reduce leakage. Thirty-day results for the third-generation valve will be reported separately at the ACC meeting.

Data analysis identified several indications and cautions for both procedures. Kidney disease was a significant issue with TAVR but not surgery; a high Society of Thoracic Surgeons risk score, which indicates the patient is sicker at the time of treatment, was a predictor of death in the surgery group; and liver disease was a significant factor in both groups. TAVR patients will be followed annually for life in the Society of Thoracic Surgeons/ACC Transcatheter Valve Therapies registry; surgery patients will not be followed beyond five years.

The U.S. Food and Drug Administration (FDA) approved the Sapien valve in November 2011 for the treatment of inoperable patients, and expanded the indication to high-risk surgical patients in October 2012. In June 2014, the FDA approved the next-generation Sapien XT valve for the treatment of both inoperable and high-risk patients. 

For more information: acc.org, www.edwards.com

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Overlay Init